NCT07075640View on ClinicalTrials.gov

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

October 17, 2025

Study Completion Date

December 12, 2025

Conditions
Healthy Participants
Interventions
DRUG

AG-236

Subcutaneous (SC) Injection

DRUG

Placebo

SC Injection

Trial Locations (1)

53704

RECRUITING

Fortrea Clinical Research Unit Inc., Madison

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY